News
Pediatric Studies of Difficult-To-Treat Cancers to Get Advisory Cmte. Review
Pediatric Studies of Difficult-To-Treat Cancers to Get Advisory Cmte. Review
M Berman-Gorvine
20110904
2011 Oct 4
The Pink Sheet Daily
Pediatric Studies of Difficult-To-Treat Cancers to Get Advisory Cmte. Review
The Pink Sheet Daily. 2011 Oct 4, M Berman-Gorvine
Sponsors and FDA are seeking detailed advice from an advisory panel on trial designs and endpoints for drugs to treat recurrent or refractory cancers in children. In its Nov. 1 meeting, the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will discuss pediatric development plans for GlaxoSmithKline's renal cell carcinoma treatment Votrient (pazopanib), Genentech's vismodegib, for which the company submitted an NDA for advanced basal cell carcinoma last month, and two investigational...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
